Technical Data
H8010-05
HRASLS, NT (H-REV107, HRASLS, HRAS-like suppressor, A-C1, HRASLS1, HSD28, H-REV107 protein-related protein)
Description:
Applications:
Suitable for use in ELISA. Other applications not tested.

Recommended Dilution:
Peptide ELISA: 1:4,000.
Western Blot: Preliminary experiments in Human Heart, Muscle and Thyroid Gland lysates gave no specific signal but low background (at antibody concentration up to 1ug/ml). Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Peptide Blocking:
Corresponding peptide is available for Peptide Blocking studies. See H8010-05-P. Antibody is typically 0.5mg/ml and peptide is supplied as a 100ul pellet. When peptide is reconstituted in 200ul water, the concentration would also be 0.5mg/ml. To start, the best ratio would be 1:1 (molar excess of peptide relative to antibody when identical volumes are mixed). Mix equal volumes of peptide and antibody at the required dilution and leave at ambient temperature. It is best is to have two identical blots to be incubated with equal amount of antibody, but one with the antibody pre-adsorbed to the peptide for 20min. Then incubate and develop the two blots in parallel.
TypeIsotypeCloneGrade
PabAffinity Purified
SizeStorageShippingSourceHost
100ug-20°CBlue IceHumanGoat
Concentration:
~0.5mg/ml
Immunogen:
A synthetic peptide from the C-terminus of aa--NDCFSLNYPGNPCP
Purity:
Purified by affinity chromatography.
Form
Supplied as a liquid in Tris saline, pH 7.2, 0.5% BSA, 0.02% sodium azide.
Specificity:
Recognizes human HRASLS. Species Crossreactivity: mouse, rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Promoter hypermethylation of CCNA1, RARRES1, and HRASLS3 in nasopharyngeal carcinoma., Yanatatsaneejit P, Chalermchai T, Kerekhanjanarong V, Shotelersuk K, Supiyaphun P, Mutirangura A, Sriuranpong V., Oral Oncol. 2007 Aug 2; [Epub ahead of print]